Search

Your search keyword '"Scholl, Sebastian"' showing total 720 results

Search Constraints

Start Over You searched for: Author "Scholl, Sebastian" Remove constraint Author: "Scholl, Sebastian"
720 results on '"Scholl, Sebastian"'

Search Results

5. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia

6. Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemia

8. Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification

10. Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

11. Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry

12. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD

13. UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome

14. Alterations of cohesin complex genes in acute myeloid leukemia: differential co-mutations, clinical presentation and impact on outcome

16. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study

26. Standardizing Nutritional Care for Cancer Patients: Implementation and Evaluation of a Malnutrition Risk Screening.

28. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

29. Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation

30. Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations

31. A phase 1 single-arm, open-label study of emavusertib (CA-4948) in combination with azacitidine and venetoclax in patients (pts) with acute myeloid leukemia (AML) in complete response (CR) with measurable residual disease (MRD).

32. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia

33. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

35. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

42. No impact of time from diagnosis to treatment on survival in newly diagnosed AML treated with venetoclax-based regimens

43. Effective bridging strategies prior to infusion with tisagenlecleucel results in high response rates and long-term remission in relapsed / refractory large B-cell lymphoma: findings from a German monocentric study.

44. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Catalog

Books, media, physical & digital resources